FGF12-Related Early-Onset Epileptic Encephalopathies: Therapeutic Response to Sodium Channel Blockers

FGF12 (FHF1) gain-of-function — voltage-gated sodium channel hyperactivity — response to sodium channel blockers (carbamazepine, phenytoin, lamotrigine)

FGF12 (FHF1)-related early-onset epileptic encephalopathies are documented to respond to sodium channel blockers (SCBs), with direct precision medicine implications. FGF12 encodes FHF1, an intracellular modulator of voltage-gated sodium channels; gain-of-function variants increase neuronal excitability through Na+ channel hyperactivation. Unlike SCN1A/Dravet syndrome (where SCBs are contraindicated), FGF12-related encephalopathies specifically benefit from SCBs such as carbamazepine, phenytoin, or lamotrigine.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

FGF12 exemplifies precision medicine in genetic epileptology: the same clinical presentation (severe epileptic encephalopathy) may require opposing treatments depending on the gene — SCBs are beneficial for FGF12 GOF while potentially deleterious for SCN1A LOF. This publication should prompt systematic FGF12 testing in any unexplained early-onset epileptic encephalopathy before initiating treatment.

Clinical impact : 3/3 · Evidence strength : 2/3 · Novelty : 1/2 · Sample size : 1/1 · Journal quality : 0/1 → Total : 7/10